メリーランド州における膠芽腫の臨床試験
メリーランド州内の拠点で、膠芽腫に関する16件の研究が参加者を募集しています。
メリーランド州内の都市
公式研究テキスト（英語）
Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
- John Hopkins University, Baltimore
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/05更新 · NCT05902169Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care
- Johns Hopkins University, Baltimore
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/05更新 · NCT07195591Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
- National Institutes of Health Clinical Center, Bethesda
被験者募集中第1/2相
18歳〜99歳 · 全性別 · 2026/09/28更新 · NCT07416188Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
- Johns Hopkins Sidney Kimmel Cancer Center - Baltimore, Baltimore
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/28更新 · NCT07326566Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, IDH Wildtype, MGMT-Unmethylated Glioblastoma
- Maryland Proton Treatment Center, Baltimore
- University of Maryland/Greenebaum Cancer Center, Baltimore
- UM Upper Chesapeake Medical Center, Bel Air
- 他1件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/10更新 · NCT07452458Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma
- National Institutes of Health Clinical Center, Bethesda
被験者募集中第1相
18歳〜120歳 · 全性別 · 2026/08/14更新 · NCT06344130PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications
- National Institutes of Health Clinical Center, Bethesda
被験者募集中第1/2相
18歳〜120歳 · 全性別 · 2026/08/12更新 · NCT06161519Collection of Blood and Urine Samples in Patients Receiving Radiation Therapy for Glioblastoma Multiforme
- National Institutes of Health Clinical Center, Bethesda
被験者募集中観察研究
18歳〜120歳 · 全性別 · 2026/08/11更新 · NCT00083512Music Therapy in Newly Diagnosed Glioblastoma After Chemoradiation Therapy (MELODY-GBM)
- Oncology- Broadway, Baltimore
被験者募集中
18歳以上 · 全性別 · 2026/06/18更新 · NCT07375992Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
- Advanced Molecular Imaging and Therapy, Glen Burnie
- United Theranostics - Chesapeake, Glen Burnie
被験者募集中第1相
18歳以上 · 全性別 · 2026/06/11更新 · NCT05283330LITT Followed by Hypofractionated RT for Newly Diagnosed Gliomas (GCC 20138)
- Maryland Proton Treatment Center, Baltimore
- University of Maryland Greenebaum Cancer Center, Baltimore
- UCH Kaufman Cancer Center, Bel Air
- 他2件
被験者募集中
18歳以上 · 全性別 · 2026/05/06更新 · NCT04699773Precision Radiotherapy Enabled by Molecular MRI
- Johns Hopkins University, Baltimore
被験者募集中
18歳以上 · 全性別 · 2026/05/06更新 · NCT07512154Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma
- Johns Hopkins Medical Institution, Baltimore
被験者募集中第1相
18歳〜100歳 · 全性別 · 2026/01/09更新 · NCT05083754Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
- National Institutes of Health, Bethesda
被験者募集中第1相
18歳以上 · 全性別 · 2025/12/18更新 · NCT04541082SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Baltimore
- Massive Bio SYNERGY-AI site, Bethesda
- Massive Bio SYNERGY-AI site, Silver Spring
- 他1件
被験者募集中観察研究
全年齢 · 全性別 · 2025/10/28更新 · NCT03452774Study of Liposomal Curcumin in Combination With RT and TMZ in Patients With Newly Diagnosed High-Grade Gliomas
- Johns Hopkins University/Johns Hopkins Hospital, Baltimore
被験者募集中第1/2相
18歳以上 · 全性別 · 2024/11/29更新 · NCT05768919ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。